APOLLO HOSPITALS ENTER. L vs EMCURE PHARMACEUTICALS L

A side-by-side comparison of APOLLO HOSPITALS ENTER. L (APOLLOHOSP) and EMCURE PHARMACEUTICALS L (EMCURE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, EMCURE PHARMACEUTICALS L leads APOLLOHOSP vs EMCURE on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

65.36
P/E ratio
36.57
13.42
P/B ratio
7.11
0.11%
Dividend yield
0.17%
₹135.04
EPS
₹48.76

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

22.10%
Return on equity
20.10%
18.00%
Return on capital
24.00%
15.00%
EBITDA margin
20.00%
7.94%
Net margin
10.22%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
15.42%
33.39%
Profit CAGR (3Y)
18.75%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.27L Cr
Market cap
₹33,810 Cr
₹25,228 Cr
Revenue
₹9,204 Cr
₹2,003 Cr
Net profit
₹941 Cr
0.90
Debt / equity
0.31
APOLLO HOSPITALS ENTER. L
  • + ["Company has delivered good profit growth of 77.8% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
  • ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
EMCURE PHARMACEUTICALS L
  • ["Stock is trading at 7.06 times its book value"]
APOLLO HOSPITALS ENTER. L full analysis EMCURE PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.